Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

Bente Glintborg; T.M. Kringelbach; Nils Bolstad; DJ Warren; Grith Petersen Eng; IJ Sørensen; Anne Gitte Loft; Oliver Hendricks; Asta Linauskas; Henrik Nordin; Salome Kristensen; Hanne Lindegaard; DV Jensen; GL Goll; Estrid Vilma Solyom Høgdall; Johanna Elin Gehin; Christian Enevold; Claus Henrik Nielsen; NS Krogh; JS Johansen; Merete Lund Hetland

doi:10.1080/03009742.2017.1376110

Abstract

As patents on originator biological disease-modifying anti-rheumatic drugs (bDMARDs) expire, biosimilar drugs are marketed. As a result of the complex manufacturing processes, a biosimilar is not c...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Glintborg et al. (2018) studied this question.

synapsesocial.com/papers/6ab489df952b5f18bf6d86b1 https://doi.org/10.1080/03009742.2017.1376110

View at Publisher

Ask AI

Bookmark

Share

Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

Abstract

Discussion

Cite This Study

Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

Abstract

Discussion

Cite This Study

Keep reading

Keep reading